Tango Therapeutics To Present Updated Data From Phase 1/2 Study Of Vopimetostat In Combination With Daraxonrasib Or Zoldonrasib In Patients With MTAPdel/RASmut Metastatic PDAC And NSCLC At ESMO Congress 2026

뉴스 본문을 불러오고 있어요.

Tango Therapeutics To Present Updated Data From Phase 1/2 Study Of Vopimetostat In Combination With Daraxonrasib Or Zoldonrasib In Patients With MTAPdel/RASmut Metastatic PDAC And NSCLC At ESMO Congress 2026 | 웨이프 WAPE

Tango Therapeutics To Present Updated Data From Phase 1/2 Study Of Vopimetostat In Combination With Daraxonrasib Or Zoldonrasib In Patients With MTAPdel/RASmut Metastatic PDAC And NSCLC At ESMO Congress 2026

기사 요약

관련 종목

댓글 —